Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells

Cancer Research

Volumn 73, Issue 10, 2013, Pages 3062-3074

  Fu, Jun ^a,b   Koul, Dimpy ^a,b   Yao, Jun ^a   Wang, Shuzhen ^a   Yuan, Ying ^c   Colman, Howard ^a   Sulman, Erik P ^d   Lang, Frederick F ^e   Yung, W K Alfred ^a,e  

^a Brain Tumor Center   (United States)

^b Departments of Neuro Oncology   (United States)

^c Departments of Biostatistics   (United States)

^d Departments of Radiation Oncology   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; NVP HSP 990; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; GLIOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NERVE CELL DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; TARGET CELL DESTRUCTION;

ANIMALS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; GLIOMA; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; NEOPLASTIC STEM CELLS; NERVE TISSUE PROTEINS; PROTEIN STABILITY; PYRIDONES; PYRIMIDINES;

EID: 84877864064     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2033     Document Type: Article

References (37)

1. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
2. Rowinsky EK. Signal events: Cell signal transduction and its inhibition in cancer. Oncologist 2003;8 Suppl 3:5-17. (Pubitemid 37523378)
3. Kim LS, Kim JH. Heat shock protein as molecular targets for breast cancer therapeutics. J Breast Cancer 2011;14:167-74.
4. Patel HJ, Modi S, Chiosis G, Taldone T. Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opin Drug Discov 2011;6:559-587.
5. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: Are we there yet? Clin Cancer Res 2012;18:64-76.
6. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 2009;4:e7752.
7. Bohonowych JE, Gopal U, Isaacs JS. Hsp90 as a gatekeeper of tumor angiogenesis: Clinical promise and potential pitfalls. J Oncol 2010; 2010:412985.
8. Staufer K, StoeltzingO. Implication of heat shock protein 90 (HSP90) in tumor angiogenesis: A molecular target for anti-angiogenictherapy? Curr Cancer Drug Targets 2010;10:890-7.
9. Khong T, Spencer A. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol Cancer Ther 2011;10:1909-17.
10. Travers J, Sharp S, Workman P. HSP90 inhibition: Two-pronged exploitation of cancer dependencies. Drug Discov Today 2012;17: 242-52.
11. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006;9: 391-403. (Pubitemid 43668737)
12. Jin X, Yin J, Kim SH, Sohn YW, Beck S, Lim YC, et al. EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res 2011;71: 7125-34.
13. Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 2011;19:498-511.
14. Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011;25: 2594-609.
15. Imitola J, Raddassi K, Park KI, Mueller FJ, Nieto M, Teng YD, et al. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A 2004;101:18117-22. (Pubitemid 40054083)
16. Tamura M, Gu J, Danen EH, Takino T, Miyamoto S, Yamada KM. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 1999;274:20693-703.
17. Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, et al. Antitumor activity of NVP-BKM120-a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 2012;18:184-95.
18. Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP. Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro-Oncol 2010;12:328-40.
19. Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, et al. NVPBEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 2009;8:2204-10.
20. Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrixattached cancer cells. Cancer Cell 2012;21:227-39.
21. Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, et al. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 2010;12:559-69.
22. Prince T, Sun L, Matts RL. Cdk2: A genuine protein kinase client of Hsp90 and Cdc37. Biochemistry 2005;44:15287-95. (Pubitemid 41681463)
23. Stepanova L, Leng X, Parker SB, Harper JW. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 1996;10:1491-502. (Pubitemid 26260706)
24. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1.Cell 1999;98: 859-69. (Pubitemid 29446902)
25. Menezes DL, Taverna P, Jensen MR, Abrams T, Stuart D, Yu GK, et al. The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo. Mol Cancer Ther 2012;11:730-9.
26. Sauvageot CM, Weatherbee JL, Kesari S, Winters SE, Barnes J, Dellagatta J, et al. Efficacy of theHSP90 inhibitor 17-AAGinhuman gliomacell lines and tumorigenic glioma stem cells. Neuro Oncol 2009;11:109-21.
27. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, et al. Glioma stem cell lines expanded in adherent culture have tumorspecific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009;4:568-80.
28. Mehta S, Huillard E, Kesari S, Maire CL, Golebiowski D, Harrington EP, et al. The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell 2011;19:359-71.
29. Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, Roy M, Quinones-Hinojosa A, VandenBerg S, et al. PDGFR alphapositive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron 2006;51:187-99. (Pubitemid 44063617)
30. Menn B, Garcia-Verdugo JM, Yaschine C, Gonzalez-Perez O, Rowitch D, Alvarez-Buylla A. Origin of oligodendrocytes in the subventricular zone of the adult brain. J Neurosci 2006;26:7907-18. (Pubitemid 44315160)
31. Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, et al. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 2007;53:503-17. (Pubitemid 46216748)
32. Barrett LE, Granot Z, Coker C, Iavarone A, Hambardzumyan D, Holland EC, et al. Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell 2012;21:11-24.
33. Mao H, Lebrun DG, Yang J, Zhu VF, Li M. Deregulated signaling pathways in glioblastomamultiforme: Molecular mechanisms and therapeutic targets. Cancer Invest 2012;30:48-56.
34. Salomoni P, Calegari F. Cell cycle control of mammalian neural stem cells: Putting a speed limit on G1. Trends Cell Biol 2010;20:233-43.
35. Jablonska B, Aguirre A, Vandenbosch R, Belachew S, Berthet C, Kaldis P, et al. Cdk2 is critical for proliferation and self-renewal of neural progenitor cells in the adult subventricular zone. J Cell Biol 2007;179:1231-45. (Pubitemid 350277741)
36. Kim H, Huang W, Jiang X, Pennicooke B, Park PJ, Johnson MD. Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci U S A 2010;107:2183-8.
37. Verhaak RG, Hoadley KA, Purdom E,WangV, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.